ArticleJournal of translational medicine2025
Potential biomarkers of idiopathic pulmonary fibrosis: metabonomics driven lipid profiling.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- Metabolic reprogramming in fibrosis-related diseases: underlying mechanisms and therapeutics.Molecular biomedicine · 2026Review
- Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling.Diagnostics (Basel, Switzerland) · 2026Review
- CAR T cell therapy for fighting IPF: perspectives on a living drug.Frontiers in immunology · 2026Review
- Identification of diagnostic and prognostic phospholipid biomarkers in idiopathic pulmonary fibrosis via machine learning and in vivo validation.Human genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease. At present, the diagnosis of pulmonary fibrosis relies on high-resolution CT and invasive lung biopsy. In view of the lack of specific serum biomarkers in the diagnosis and monitoring of IPF, it is urgent to adopt an integrated metabolomics analysis strategy to screen and verify specific potential biomarkers, and to establish their translational value in the diagnosis, severity and prognosis of IPF.
objectivesIn this study, an integrated metabolomics analysis strategy was used to screen and validate specific potential biomarkers for the diagnosis and evaluation of IPF severity and prognosis.
methodIn this study, the serum metabolome of the two groups was compared by liquid chromatography-mass spectrometry (LC-MS) to study the characteristics of metabolic changes related to the disease (n = 30) and to screen potential biomarkers. Then multivariate regression analysis and correlation network modeling were used to analyze the correlation between target metabolites and pulmonary function parameters, hematological parameters and coagulation function parameters.
resultsMultiple pathways related to lipid metabolism were enriched in IPF patients compared to controls, including cholesterol metabolism, sphingolipid metabolism, steroid metabolism, and biosynthetic terpenoid metabolism. In addition, 37 compounds related to lipid metabolism were enriched in IPF patients, among which Palmitoyl ethanolamide (PEA) and 2-amino-1,3,4-octadecanetriol were significantly increased. ROC curve analysis, Kaplan-Meier application analysis model and multivariate Cox regression analysis showed that the two potential biomarkers could be used for the diagnosis and prognosis evaluation of IPF.
conclusionThis study clarified that metabolic reprogramming and lipid metabolism disorder are significant characteristics of IPF. PEA and 2-Amino-1,3,4-octadecanetriol May be potential biomarkers for patients with IPF and have diagnostic and prognostic evaluation value for IPF. HIGHLIGHTS: Through systematic metabolomics analysis, two novel serum lipid metabolites were identified as potential biomarkers for IPF for the first time. It has been confirmed that IPF patients exhibit significant reprogramming of lipid metabolism. It was the first time that 2-amino-1,3,4-octadecanetriol was reported to have a significant positive correlation with the abnormal coagulation function indicators (APTT, Fib, D-dimer) in patients with IPF. This provides a new metabolic perspective for understanding the pathophysiological mechanism of the increased risk of venous thromboembolism (VTE) in IPF patients. Both of the two potential biomarkers were negatively correlated with hemoglobin. This connects the often overlooked IPF complication of nutritional metabolism imbalance (such as anemia) with the disease-specific metabolic changes, highlighting the importance of paying attention to the nutritional status in the management of IPF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.